RPG Life Sciences (RPGLIFE) Q3 24/25 earnings summary

Executive summary

• Integrated pharmaceutical company with strong presence in domestic and international markets, focusing on branded formulations, generics, and APIs.

• Transformation agenda centers on growth, margin improvement, digitalization, and organizational strengthening.

• Unaudited financial results for the quarter and nine months ended December 31, 2024, were approved by the Board of Directors on January 24, 2025.

• The company operates solely in the Pharmaceuticals segment.

• Recognized for value creation, fair business practices, and industry awards.

Financial highlights

• Q3 FY25 revenue from operations rose 12% year-over-year to ₹172.7 Cr; EBITDA up 32% to ₹52.5 Cr; PAT up 32% to ₹34.9 Cr; EPS up 32% to ₹21.1.

• 9M FY25 revenue grew 12% year-over-year to ₹510.3 Cr; EBITDA up 26% to ₹141.8 Cr; PAT up 25% to ₹93.1 Cr; EPS up 25% to ₹56.3.

• Revenue from operations for Q3 FY25 was ₹17,271 lakhs, up from ₹15,370 lakhs in Q3 FY24.

• Net profit for Q3 FY25 stood at ₹3,493 lakhs, compared to ₹2,646 lakhs in Q3 FY24.

• Adjusted 9M FY25 PBT and PAT margins (excluding ₹27.3 Cr exceptional item) at 24.8% and 18.2% respectively.

Outlook and guidance

• Transformation agenda to continue driving growth, margin expansion, and operational efficiency.

• Focus on domestic and global business expansion, modernization, R&D pipeline, and M&A opportunities.

• The company expects to complete the assignment of surplus leasehold land for ₹14,563 lakhs in Q4 FY25, pending necessary approvals.

• The company is actively working to minimize business loss from the recent fire incident and expects insurance coverage to mitigate financial impact.